A recombinant live vector vaccine was produced by insertion of cDNA encoding the structural proteins (P1) of foot-and-mouth disease virus (FMDV) into a replication-competent human adenovirus type 5 vaccine strain (Ad5 wt). Groups of cattle (n l 3) were immunized twice, by the subcutaneous and/or intranasal routes, with either the Ad5 wt vaccine or with the recombinant FMDV Ad5-P1 vaccine. All animals were challenged by intranasal instillation of FMDV 4 weeks after the second immunizations. In the absence of a detectable antibody response to FMDV, significant protection against viral challenge was seen in all of the animals immunized twice by the subcutaneous route with the recombinant vaccine. The observed partial protection against clinical disease was not associated with a reduction in titre of persistent FMDV infections in the oropharynx of challenged cattle.
Introduction
Infection with live micro-organisms usually induces a potent and long-lasting immune response, in contrast to the immunity elicited by inactivated or soluble antigens, which is generally weaker and of reduced duration . The more efficient induction of protective immunity by live vaccines compared to inactivated antigens has been reported for viruses, including those of the family Picornaviridae. Poliovirus is one such example, and in this case the induction of high neutralizing antibody titres has been associated with protection (Usherwood & Nash, 1995) . The improved performance of live vaccines is consistent with a requirement for a broad spectrum of immune mechanisms to achieve an efficient immune response to natural infections. One strategy to present foreign antigens in a replicative form is the use of recombinant viral vectors. Recombinant adenoviruses have been shown recently to be an efficient system for the expression and presentation of foreign antigens and to elicit potent humoral, both systemic and mucosal, and cellular immune responses in humans (Gaydos & Gaydos, 1995) as well as in a number of animal hosts Gallichan et al., 1995 ; Gaydos & Gaydos, 1995 ; Hsu et al., 1994 ; Kadoi, 1997 ; Lubeck et al., 1994 ; Mittal et al., 1996 ; Randrianarison-Jewtoukoff & Perricaudet, 1995 ; Torres et al., 1995 ; Xiang et al., 1996) .
Foot-and-mouth disease virus (FMDV) is a picornavirus that affects artiodactyls, importantly cattle and swine, and is responsible for the most contagious of all animal diseases (Pereira, 1981) . Control of the disease in endemic areas is carried out with inactivated whole virus vaccines that induce a serotype-restricted, short-lived protection, making frequent revaccination a prerequisite in control campaigns (Barteling & Vreeswijk, 1991) . Attempts to induce protection by means of recombinant or synthetic FMDV antigens have resulted in limited protection (Brown, 1988 ; Taboga et al., 1997) , emphasizing the lack of adequate immune stimuli provided by non-replicating, viral subunits. On the other hand, parenteral administration of conventional FMD vaccine does not prevent the persistent infection of protected ruminants with FMDV, which has epidemiological implications. In this report we have analysed the immune response induced in cattle by a recombinant adenovirus that expresses the precursor polyprotein (P1) of the four FMDV capsid proteins. In addition to protection against clinical disease, we have examined the induction of mucosal immunity following intranasal immunization with the adenovirus-FMDV recombinant vaccine (Ad5-P1), and the effect of this response on FMDV persistence post-challenge.
Methods
Viruses and plasmids. Human adenovirus type 5 wild-type vaccine strain (Ad5 wt) and the Ad5-derivative plasmids pFG144K3 (Bett et al., 1993) , pFG173 (Hitt et al., 1995) and pFG140 (Graham et al., 1988) , were provided by F. L. Graham (McMaster University, Ontario, Canada) .
PRB21-P1, containing the P1 sequence, was constructed as described (Sanz-Parra et al., 1998) . Recombinant Ad5 wt and recombinant Ad5-P1 virus stocks were grown and titrated in 293 cell cultures as described (Graham & Prevec, 1991) . FMDV C1 Oberbayern (10( TCID &! in 2 ml M\25 buffer) was used for animal challenge. The virus was grown in BHK-21 cells, and supernatants of infected cells were clarified and stored at k70 mC. Titres of the viral stocks were determined by plaque assay in BHK-21 cells (Domingo et al., 1980) , and are expressed as p.f.u.\ml.
Cell cultures. BHK-21, IB-RS-2, and Graham's 293 human foetal kidney cells (Graham et al., 1977) , were obtained from the ATCC and maintained as monolayer cultures in Eagle's minimum essential medium (DMEM), supplemented with 10 % (v\v) foetal bovine serum.
FMDV vaccine. The vaccine was prepared from a type C1 Oberbayern FMDV inactivated antigen concentrate (Bayer, Cologne, Germany) held in the International FMD Vaccine Bank (IVB), Pirbright, UK. The formulated vaccine contained 2n88 µg 146S antigen per 2n0 ml dose, and was prepared as a water-in-oil-in-water emulsion with Montanide ISA 206 (Seppic, Paris, France) as previously described (Barnett et al., 1996) .
Construction of recombinant adenovirus-P1. Ad5 recombinant virus expressing FMDV P1 polypeptide was constructed as described in Fig. 1 using standard protocols. The 2n4 kb HindIII-EcoRI fragment corresponding to P1 was excised from PRB21-P1. Both P1 fragment and XbaI-digested pFG144K3 plasmid were treated with Klenow and T4 DNA polymerase to obtain blunt ends. Digested plasmids and DNA fragments were electrophoresed in agarose and the bands purified from the gel. The P1 fragment was ligated into the XbaI site in pFG144K3 plasmid vector, which contains the 3h-end of Ad5 and has a deletion in E3. The resulting plasmid, pFG144K3-P1, which carries the P1 sequence within the E3 region in parallel to the E3 promoter, was cotransfected into 293 cells with plasmid pFG173, which contains the 5h end of Ad5, with a lethal deletion in the E3 region (Mittal et al., 1993 ; Hitt et al., 1995) . Plasmid cotransfections were carried out using the lipofectine method as described (Rose et al., 1991) . Viral plaques were isolated after 12-14 days, and expanded in 293 cells. Infectious recombinant Ad5-P1 were twice plaque-purified on 293 cells. Viral DNA was purified as described (Torres et al., 1995) , digested with the appropriate restriction enzymes and analysed in agarose electrophoresis. (Sanz-Parra et al., 1998) . Fixation for immunofluorescent analysis was by immersion in methanol for 5 min at k20 mC, followed by washing in PBS. In both assays a MAb, SD6, was used for the specific detection of P1 expression. MAb SD6 recognizes a continuous antigenic site located at position 140-160 of FMDV C-S8 VP1 (Mateu et al., 1990) . Bound SD6 was detected in whole cells by incubation with FITC-conjugated anti-mouse antibody.
Analysis of FMDV P1 expression.
Animal inoculation. Twelve Friesian-Hereford cattle, 12-18 months old, were placed into four groups and inoculated as follows. Group A (TB34-36) : 10* p.f.u. Ad5 wt in 2 ml 0n1 M PBS by silicon tube into the nasopharynx and subcutaneously (right shoulder) on days 1 and 28. Group B (TB31-33) : 10* p.f.u. recombinant Ad5-P1 in 2 ml PBS by silicon tube into the nasopharynx and subcutaneously (right shoulder) on days 1 and 28. Group C (TB28-30) : 10* p.f.u. recombinant Ad5-P1 in 2 ml PBS by silicon tube into the nasopharynx and subcutaneously (right shoulder) on day 1, and 10* p.f.u. recombinant Ad5-P1 in 2 ml PBS by silicon tube into the nasopharynx only on day 28. Group D (TB25-27) : 2 ml C1 Oberbayern standard IVB vaccine, intramuscularly in the right rump on day 1 and the same immunization on day 28 in the left rump.
Samples of venous blood and oropharyngeal fluid (probang sample) (Sutmoller & Gaggero, 1965) were collected weekly to determine anti-FMDV Type C antibody titres by virus neutralization test (VNT) and ELISA in sera and in probangs by IgA-and IgG1-specific ELISA. Titres of FMDV in probang fluid samples, diluted 1 : 1 in 30 mM HEPES-buffered Eagle's medium, were determined on primary bovine thyroid cell culture tubes (Snowdon, 1966) . Cattle were challenged on day 55 (week 8) by intranasal inoculation of 10( TCID &! FMDV C1 Oberbayern in 2 ml M\25 buffer. After challenge, rectal temperatures and clinical signs were monitored daily, and probang and blood samples were collected weekly for 4 weeks.
Serology.
Neutralizing antibody titres to type C1 Oberbayern FMDV in serum samples were measured in a micro-neutralization assay using IB-RS-2 cells, essentially as described by Golding et al. (1976) for swine vesicular disease. End-point titres were calculated as the reciprocal of the last serum dilution to neutralize 100 TCID &! of FMDV in 50 % of the wells. In addition, antiviral antibody was measured in an indirect trapping ELISA, as previously described (Barnett et al., 1996) . End-point titres were calculated as the absorbance in A %*# units, of a 1 : 320 dilution of serum samples (day 0 values were subtracted). Serum antibody titres to Ad5 were determined by direct ELISA. Briefly, ELISA plates (Nunc) were coated overnight with a crude cell culture harvest of Ad5 at approximately 8 µg protein\ml. Duplicate dilution series of sample sera were added, and bound antibody was detected with a goat anti-bovine immunoglobulin-horseradish peroxidase conjugate (Dakopatts). Endpoint titres were calculated as the absorbance, in A %*# units, of a 1 : 640 dilution of serum samples (day 0 values were subtracted).
Probang antibody measurement.
IgA and IgG1 antibody responses to FMDV type C1 Oberbayern were measured in probang samples by isotype-specific ELISA as previously described (Salt et al., 1996) . Titres were calculated as A %*# of a 1 : 2 dilution of samples (day 0
Partial protection against FMD by Ad5-P1 Partial protection against FMD by Ad5-P1 values were subtracted). IgA antibody responses to Ad5 in probang samples were measured largely as above for the detection of antibody in serum. In this case, an anti-bovine IgA-specific monoclonal antibody (ID-DLO, Lelystat, The Netherlands) was used to detect Ad5-specific IgA in duplicate dilution series of probang samples, followed by the addition of rabbit anti-murine immunoglobulin-horseradish peroxidase conjugate (Dakopatts). End-point titres were calculated as for FMDV-specific IgA in probang samples. Virus isolation and titration. The infectivity of oropharyngeal fluid samples was measured by inoculation of monolayers of primary calf thyroid (BTY) cells, essentially as described by Ferris & Dawson (1988) . Five BTY tubes were used for each dilution. Inoculated BTY tubes were incubated at 37 mC on roller drums and examined daily for 4 days for evidence of CPE. The specificity of CPE was confirmed in an antigen detection ELISA (Roeder & Le Blanc Smith, 1987) .
Results

Construction and characterization of Ad5-P1 recombinant
The Ad5-P1 recombinant expressing the P1 polypeptide was constructed using a replication-competent Ad5 vector by inserting the FMDV P1 sequence into the E3 region of the Ad5 genome. The intermediate plasmids used for the cloning of P1 were pFG144K3 and pFG173. Both plasmids are noninfectious, but generate infectious virus following cotransfection of 293 cells (Bett et al., 1993 ; Mittal et al., 1993) , resulting in a recombinant adenovirus containing the genes cloned into the E3 region of plasmid pFG144K3. The cloning scheme is shown in Fig. 1 , and the general procedure was essentially as described by Torres et al. (1995) . The FMDV P1 insert, including both translation-initiation and -termination codons, contains the coding sequences of the entire P1 and 2A, and the C-terminal sequence of 2B from type C1 FMDV (C-S8). Since it has been reported that insertion of exogenous promoters does not result in better expression of the downstream gene (Torres et al., 1995 ; Yarosh et al., 1996) , we introduced the P1 gene into the XbaI site in pFG144K3 by blunt-end ligation, resulting in plasmid pFG144K3-P1, which carries the P1 sequence within the E3 deletion, directly under the control of the endogenous E3 promoter. Plasmids pFG144K3-P1 and pFG173 were used to cotransfect 293 cells to generate Ad5-P1 infectious virus by intracellular recombination. The recombinant Ad5 viruses generated in the cotransfection were cloned and purified as described in Methods. To confirm that the clones had the correct structure, the DNA from the Ad5 recombinants was digested with restriction endonucleases and analysed by agarose gel electrophoresis. The expression of FMDV P1 polypeptide in HeLa cells infected with Ad5-P1 recombinant virus was analysed by Western blot and immunofluorescence ( Fig. 1 b, c) . Maximum expression of P1 detected by immunofluorescence was reached at 48 h post-infection, and the expressed polypeptide had an apparent molecular mass of 85 kDa. Cells not infected with Ad5-P1 or infected with Ad5 wt were negative in both assays (data not shown).
Systemic and mucosal responses to FMDV in Ad5-P1-immunized cattle
To determine the ability of a recombinant adenovirus-FMDV vaccine to induce mucosal and systemic immunity, cattle were inoculated on days 1 and 28 with Ad5-P1 recombinant virus by a combined intranasal and subcutaneous route (group B), or by a combined intranasal and subcutaneous route at day 1 and intranasally only at day 28 (group C). In addition, a group of cattle was inoculated on days 1 and 28 with Ad5 wt as a negative control (group A), and another group was inoculated intramuscularly, at the same days, with the FMD conventional vaccine (group D). Antibody responses induced in the vaccinated animals are shown in Fig. 2 . Serological anti-FMDV type C responses were determined by microneutralization test and ELISA (Fig. 2 a, b) . None of the cattle immunized with the recombinant Ad5-P1 (groups B and C) or the wild-type Ad5 virus (group A) developed detectable serological responses to FMDV before challenge. However, all animals developed serological responses within 1 week of challenge, which were of similar titre and kinetics and peaked at 2 weeks post-challenge (Fig. 2) . In group D animals, primary immunization with the conventional FMD vaccine induced high titre FMDV-specific serological responses, which were boosted by the secondary immunization. Despite the absence of clinical FMD in this group (see Table 1 ), challenge was associated with a small boost to serum antibody titres, indicative of some virus replication.
The presence of FMDV-specific antibodies in probang samples was determined as an indicator of mucosal humoral immunity. As was found for the serological responses, FMDVspecific IgA and IgG1 responses in probang samples were detected only after challenge in all animals immunized with the Ad5 or Ad5-P1 virus (Fig. 2 c, d ). IgG1 responses were detectable 1 week after challenge, peaked at 2 weeks postchallenge and fell to baseline titres after a further 2 weeks (not shown). Peak mean IgG1 titres were greater in groups A and C than in group B, possibly due to the partial protection induced in group B animals. IgA responses in all three groups continued to rise up to the point of slaughter at 4 weeks postchallenge (not shown). Animals immunized with the conventional C1 Oberbayern FMD vaccine (group D) developed IgA and IgG1 responses that were detectable in probang samples 2 weeks after the secondary immunization. Whereas high titre anamnestic IgA responses were elicited by 2 weeks post-challenge in this group (Fig. 2 d) , challenge had no obvious effect upon the IgG1 responses stimulated by the secondary vaccination (Fig. 2 c) , which were falling at the time of challenge (not shown).
Cattle immunized with Ad5 wt or Ad5-P1 developed similar primary systemic anti-Ad5 responses, detectable from 1 week after primary inoculation. However, a second subcutaneous immunization was necessary to boost this response, as animals inoculated intranasally only at day 28 did not show GHD A. Sanz-Parra and others A. Sanz-Parra and others a systemic anti-Ad5 secondary response (Fig. 2 e) . To examine the mucosal humoral immunity induced with the Ad5 vector, an IgA-specific sandwich ELISA was used to measure anti-Ad5 responses in probang samples. None of the animals developed clear anti-Ad5 IgA responses which were detectable with this assay (not shown).
Protection of immunized animals against FMDV challenge
To determine the ability of the recombinant Ad5-P1 to induce protection against FMD, cattle were challenged by intranasal inoculation of 10( TCID &! FMDV type C1 Oberbayern 4 weeks after the second immunization. Clinical signs (the development of mouth and feet lesions) and rectal temperatures were recorded daily for 4 weeks. Animals were considered to be partially protected against FMD if the onset of pyrexia (rectal temperature 39n5 mC) post-challenge was delayed and\or the duration of pyrexia was reduced, and in addition the development of FMD lesions was delayed and restricted in distribution. As animals were inoculated with FMDV via the intranasal route into the nasopharynx, the absence of lesions in the feet following generalization was considered to be more significant than local spread to the tongue. On this basis, the development of a single tongue lesion only was considered to be a significant level of protection. Response after challenge Fig. 2 . FMDV-specific and Ad5-specific antibody responses in sera and probang samples of cattle immunized with Ad5-P1 recombinants. Groups of cattle (n l 3) were immunized intranasally and subcutaneously with Ad5 wt on days 1 and 28 (group A), or with Ad5-P1 (group B), or with Ad5-P1 intranasally and subcutaneously on day 1 and intranasally only on day 28 (group C), or with conventional inactivated FMDV vaccine intramuscularly on days 1 and 28 (group D) (vaccinated control). Cattle were challenged on day 55 (week 8) intranasally with 10 7 TCID 50 FMDV C1. Probang and blood samples were collected weekly from day 1 to 4 weeks after challenge. Data represent the mean antibody titre of each group of animals at week 2 (primary response), week 6 (secondary response) and week 10 (response after challenge).
As shown in Table 1 , cattle in group A, immunized with Ad5 wt, and group C, which received a secondary immunization with Ad5-P1 intranasally only, showed a similar picture of pyrexia within 3-5 days of challenge, and of 3-4 days duration. All six of these cattle developed lesions in the mouth and on all four feet by 6 days post-challenge. However, the animals that received primary and secondary immunizations with Ad5-P1 both subcutaneously and intranasally (group B) showed a significant level of protection : two of the cattle developed only a single tongue lesion, no feet lesions, and transient pyrexias of 1 day duration at 6 and 8 days postchallenge respectively. The third animal in this group developed a delayed pyrexia 6 days post-challenge, a single tongue lesion, and lesions on three feet by 8 days postchallenge. Control animals (group D) immunized with the conventional FMD vaccine were fully protected and developed no FMD lesions or pyrexias.
Analysis of the development of persistent infection post-challenge
To investigate the influence of vaccination on the development of persistent infection of the oropharynx with 
GHF
* Pyrexia defined as rectal temperature 39n5 mC. † Single discrete lesion on tongue. ‡ One foot showed FMD lesions at 6 days post-challenge, and three feet only by 8 days post-challenge. TB28  0n70  3n70  1n70  C  TB29  0n45  1n45  1n45  C  TB30  3n45  1n45  2n45  C  D  TB25  1n20  0n45  0n45  C  TB26  0n95  1n45  1n20  C  TB27 0n70 0n70 0n00 C * FMDV serotype in BTY tube supernate fluid as determined by ELISA. † Log "! TCID &! \ml on BTY tubes, calculated by the Spearman-Karber method. , Not done ; , no sample available for assay.
FMDV, we determined the titre of virus in probang samples on BTY cell culture. Probang samples collected from all animals had measurable titres of FMDV at 22 or 30 days postchallenge (Table 2) ; only one animal (TB27) was apparently virus negative 30 days post-challenge. At 30 days postchallenge the mean titre of FMDV in the probang samples from the cattle vaccinated conventionally was significantly lower (P l 0n01) than the three other groups. There were no significant differences between the mean probang sample FMDV titres of any of the other groups post-challenge at equivalent time points.
Discussion
Despite the numerous studies designed to investigate the immune response to FMDV infection, the mechanisms that are involved in protection against FMD are not fully clear. Therefore, issues such as the immune mechanisms that provide long-lasting convalescent immunity, and those acting in the animals which are protected despite the absence of neutralizing antibody, need to be determined. A likely reason for the relatively poor immunity elicited with the inactivated viral vaccines is that antigen presentation is determined by the form in which the protein is inoculated into the animal, which in the case of FMD vaccine is as an extracellular soluble antigen. This kind of immunization in general results in the induction of specific antibodies and CD4 + T helper cells, but does not stimulate efficiently other lymphocytes, such as the CD8 + T cells which usually play an important role in antiviral responses (Zinkernagel, 1996) .
The aim of this work was to investigate the protective potential and the immune response induced by a different approach to immunization, in which the antigen is expressed in the immunized animal by a recombinant viral vector, thus allowing the processing and presentation of viral epitopes in a more similar way to natural infection. As FMDV infects the respiratory tract and the skin epithelia of the host, we used a viral vector whose tropism includes these tissues. Although there are no reports on the tropism and infection of cattle by Ad5, it has been shown that this virus infects the respiratory and gastrointestinal tracts of swine (Torres et al., 1996) , and permissively infects MDBK cells (Prevec et al., 1989) . In addition, similarly constructed recombinant Ad5 viruses induce protective immunity against other viral pathogens affecting rats and swine (Torres et al., 1995 ; Mittal et al., 1996) . For this study we cloned into an adenovirus vector the gene which expresses the precursor polyprotein of the four capsid proteins (P1) of FMDV. This polyprotein was chosen as it has been shown to contain most of the continuous and discontinuous B cell epitopes involved in the induction of neutralizing antibodies to FMDV (Bittle et al., 1982 ; Strohmaier et al., 1982 ; Saiz et al., 1994 ; Abrams et al., 1995 ; Brown, 1995 ; Mateu, 1995) , as well as T-cell epitopes recognized by cattle and swine (Collen, 1994 ; Rodriguez et al., 1994 ; van Lierop et al., 1995) . The conformation of the expressed products of this gene cloned into baculovirus and vaccinia vectors has been shown to be antigenically similar to native capsid proteins (Saiz et al., 1994 ; Sanz-Parra et al., 1998) . However, the intracellular expression of the P1 antigen would have favoured MHC Class I-restricted T-cell responses, which are not in any case conformation-dependent.
Assembled FMDV capsids would be expected to be more immunogenic than the P1 polyprotein, but the inclusion of viral genes encoding the non-structural proteins necessary for the efficient processing of the P1 polyprotein has disadvantages. The L protein is a protease involved in capsid maturation which also interferes with 5h cap-dependent cellular mRNA translation (reviewed in Porter, 1993) and similarly 3C interferes with cellular RNA transcription (Falk et al., 1990 ; Martinez-Salas & Domingo, 1995) and prevented the rescue of vaccinia virus from cells expressing 3C (cited in Sanz-Parra et al., 1998) .
As shown in Table 1 , animals inoculated with the Ad-P1 recombinant showed a substantial reduction in clinical signs of FMD following virus challenge. This protection was only achieved in cattle immunized twice with a combined subcutaneous and intranasal inoculation of Ad5-P1 virus (group B), but not in the group which received only an intranasal inoculation at the second immunization (group C). This result suggests that in our system, the inclusion of a subcutaneous inoculation was necessary to confer protection against challenge, and that intranasal immunization alone failed to induce either systemic or mucosal immunity.
An exhaustive analysis of sera and probang samples collected weekly from the animals (Fig. 2) revealed, as expected, the presence of neutralizing antibodies as well as IgG and IgA anti-FMDV antibodies in animals vaccinated with inactivated FMDV (group D). Interestingly, none of the cattle immunized with the Ad-P1 recombinant (groups B and C) developed detectable systemic or secreted anti-FMDV IgG or IgA antibodies before challenge, in spite of the ability of this recombinant to confer partial protection against FMDV (group B). The most likely explanation for these results, one that has been described in other studies using recombinant virus vectors (Sanz-Parra et al., 1998) , is that the P1 polyprotein is expressed solely in the cytoplasm of infected cells, thus limiting its recognition by circulating B cells. This result suggests that the anti-FMDV protective effect elicited by Ad5-P1 in group B was probably mediated by a T-cell\cytokine response. The primary-type antibody responses measured in group A, B and C animals following challenge with FMDV is further evidence of the inability of Ad5-P1 to prime the humoral immune system. This deficiency may have contributed to the partial nature of the protection against challenge with FMDV observed in this study.
In contrast to other reports that show the efficacy of recombinant Ad5 vectors in inducing mucosal immune responses (Gallichan et al., 1993 ; Mittal et al., 1996) , we were unable to detect consistently either anti-FMDV or anti-Ad5 (not shown) IgA or IgG responses in probang samples from animals immunized with recombinant Ad5-P1 or the wildtype (Fig. 2 c, d ). This finding suggests that in this study the vector did not replicate well at mucosal sites, which could also contribute to the partial nature of the protection observed and the absence of any reduction in virus excretion post-challenge. It may be that the limited immune response observed in cattle in this study compared to that induced in other species, such as swine, was due to the low infectivity of Ad5 in this animal system. Secondary parenteral immunization with conventional FMD vaccine did stimulate detectable secreted antibody responses to FMDV, more particularly IgG1, which was probably serum-derived. However, the analysis of probang fluid FMDV-specific IgA responses to FMDV challenge indicated its local origin. In these animals, local FMDV replication in the absence of clinical disease was sufficient to stimulate an anamnestic IgA response which was absent in the cattle immunized with the recombinant Ad5-P1. Insufficient stimulation of local mucosal immunity by Ad5-P1 may also have contributed to the partial nature of the protection seen in this study with the vector vaccine.
There was no indication that any of the immunization strategies used in this study affected the development of persistent FMDV infection post-challenge. However, the significantly lower titres of FMDV in probang fluid samples from group D animals suggest that the immunity stimulated by conventional FMD vaccine can reduce the detectable titre of FMDV in the oropharynx post-challenge, possibly by limiting the foci of virus infection in this site in the early stages of establishment of persistent infection. Therefore whatever nonhumoral systemic immune mechanism was responsible for the partial protection of group B animals had no effect upon the establishment of the FMDV carrier state or titre of FMDV isolated during persistent FMDV infection of the pharynx. In GHH contrast, and in agreement with other reports (Doel et al., 1994) the relative reduction of post-challenge FMDV titres in probang samples from the conventionally vaccinated cattle (group D) in our study may be a result of the strong systemic and\or mucosal humoral responses to this form of immunization.
The present report demonstrates the limited potential of an Ad5 vector-based vaccine expressing the P1 polypeptide of FMDV to immunize and protect cattle against FMD, and indicates that immune mechanisms other than the induction of specific antibodies participate in the protection against disease. FMDV-specific T cell responses have been shown in pigs immunized with Ad5-P1 (V. Ley, unpublished data) and in guinea-pigs immunized with a vaccinia virus-P1 construct (Sanz-Parra et al., 1998) . It is possible therefore that the partial protection observed here in cattle immunized with the Ad5-P1 vector is mediated by cellular immune mechanisms in the absence of specific antibody.
